Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589356 | 0.81 | SIRT6 (0.55) | MAPTALDH1A1SIRT6MAPK1 | |
| SCHEMBL28989562 | 0.80 | MAPT (0.51) | MAPTALDH1A1HPGDKMT2AMAPK1 | |
| SCHEMBL28891048 | 0.78 | CHRNA7 (0.45) | MAPTALDH1A1GAAHPGDKMT2A | |
| SCHEMBL6189229 | 0.77 | MAPT (0.54) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL589160 | 0.77 | LMNA (0.59) | MAPTALDH1A1SIRT6HPGDMAPK1 | |
| SCHEMBL3440420 | 0.77 | MAPT (0.54) | MAPTALDH1A1GAAWDR5HPGD | |
| SCHEMBL592770 | 0.76 | L3MBTL3 (0.37) | L3MBTL3TMEM97SIGMAR1 | |
| SCHEMBL3440216 | 0.76 | MAPT (0.59) | MAPTALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL111292 | 0.75 | LMNA (0.66) | MAPTALDH1A1GAASIRT6HPGD | |
| SCHEMBL19633456 | 0.75 | MAPT (0.51) | MAPTALDH1A1GAASIRT6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120932-B1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-07-09 | — | — | EP | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| CN-101594862-A | Substituted indazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-12-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | MAPT 2569/4885ALDH1A1 1771/4885GAA 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.